Clinical trial NCT06931197: Why Wait? Initiating Contingency Management in Traumatically Injured Patients During Hospitalization
Official title: Why Wait? Initiating Contingency Management in Traumatically Injured Patients During Hospitalization
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Contingency Management
Methamphetamine Use Disorder
Keywords: Contingency management
Methamphetamine Use Disorder
Contingency management during acute hospitalization
Contingency management in Trauma Injured Patients
Lead sponsor: Queen's Medical Center
Sponsor class: OTHER
First posted: 2025-04-17
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Participants will be assigned to the CM intervention group and for the total of 12 weeks, he/she will be followed up three times a week during the hospitalization and up to three times per week as an outpatient to engage in intervention.
Primary purpose: TREATMENT

Brief summary: This clinical trial is to implement contingency management (CM) as an intervention tool to address methamphetamine use and will be initiated during inpatient acute hospitalization in trauma injured patients.

The goals are:

* Gather effectiveness data on a CM program for participants in Hawaii who use methamphetamine during hospitalization and following discharge due to trauma injury
* To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program.
* To assess the rate of leaving against medical advice (AMA) and treatment completion in acute hospital setting in participants.
* To assess the optimal timing of CM initiation for traumatically injured hospitalized patients by comparing patient outcomes (i.e. duration of CM participation and rates of CM program completion and providing negative urine samples) to NCT06532370 where CM was initiated after discharge from the hospital.

For total of 12 weeks, participants will:

* Be visited on Mondays, Wednesdays and Fridays by the research team to complete urine analysis during the hospitalization
* Visit a follow up clinic up to 3 times per week on Mondays, Wednesdays and Fridays to complete urinalysis following discharge from the hospital
* Complete Treatment Effectiveness Assessments at 6 and 12 weeks
* Engage in qualitative interview at the end of the CM program


Eligibility criteria: Inclusion Criteria:

* Admitted trauma patients
* Age greater than 18 years old
* Urine drug screen positive for methamphetamines during the current hospitalization
* Report at least weekly methamphetamine use
* First methamphetamine use greater than 6 months prior to injury
* Report at least 4 Diagnostic and Statistical Manual of Mental Disorders 5th Edition, Amphetamine-Type Substance Use Disorder symptoms (at least moderate disease)
* Glasgow Coma Scale ≥13 upon arrival to the emergency department
* Ability to understand and participate in study procedures
* Ability to communicate in English
* Expected discharge date within 45 days on the day of screening / recruitment

Exclusion Criteria:

* Active psychosis (reporting auditory or visual hallucinations)
* Under ongoing cardiorespiratory monitoring
* Evidence of moderate or severe traumatic brain injury
* Patients who are known to be pregnant
* Prisoners
* Individuals incarcerated at the time of their hospitalization
* Individuals lacking capacity to provide, or are otherwise unable or unwilling to provide written informed consent

Primary outcomes:
measure: Treatment Effectiveness Assessments (TEA) at 6- and 12-weeks post-enrollment
timeFrame: From enrollment to 6 and 12 weeks
Secondary outcomes:
measure: Conduct qualitative interviews with participants post-program
timeFrame: At the end of the treatment at 12 weeks
Other outcomes:
measure: Assessment of rate of AMA and treatment completion in acute hospital setting in participants
timeFrame: From enrollment to the end of treatment at 12 weeks
Locations:
city: Honolulu
country: United States
facility: The Queen's Medical Center
state: Hawaii
Study officials:
References: